Griseofulvin is a Oral Suspension in the Human Prescription Drug category. It is labeled and distributed by Cosette Pharmaceuticals, Inc.. The primary component is Griseofulvin.
| Product ID | 0713-0850_ec12736b-25fb-dea8-e053-2995a90a2d02 |
| NDC | 0713-0850 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Griseofulvin |
| Generic Name | Griseofulvin |
| Dosage Form | Suspension |
| Route of Administration | ORAL |
| Marketing Start Date | 2022-11-01 |
| Marketing Category | ANDA / |
| Application Number | ANDA065438 |
| Labeler Name | Cosette Pharmaceuticals, Inc. |
| Substance Name | GRISEOFULVIN |
| Active Ingredient Strength | 125 mg/5mL |
| Pharm Classes | Decreased Mitosis [PE], Microtubule Inhibition [PE], Tubulin Inhibiting Agent [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
| Marketing Start Date | 2022-11-01 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0472-0013 | Griseofulvin | Griseofulvin |
| 0713-0850 | Griseofulvin | Griseofulvin |
| 0781-5514 | Griseofulvin | Griseofulvin |
| 0781-5515 | Griseofulvin | Griseofulvin |
| 42794-012 | Griseofulvin | Griseofulvin |
| 42794-013 | Griseofulvin | Griseofulvin |
| 42794-014 | Griseofulvin | Griseofulvin |
| 62135-968 | Griseofulvin | Griseofulvin (microsize) |
| 64980-184 | Griseofulvin | Griseofulvin |
| 64980-185 | Griseofulvin | Griseofulvin |
| 64980-186 | Griseofulvin | Griseofulvin |
| 68682-519 | Griseofulvin | Griseofulvin |
| 68682-520 | Griseofulvin | Griseofulvin |
| 0884-0763 | Gris-PEG | griseofulvin |
| 0884-0773 | Gris-PEG | griseofulvin |
| 53808-0261 | Gris-PEG | GRISEOFULVIN |
| 62135-496 | Griseofulvin MICROSIZE | griseofulvin |
| 62135-494 | Ultramicrosize Griseofulvin | Griseofulvin |
| 62135-495 | Ultramicrosize Griseofulvin | Griseofulvin |